Selected
Reports from
The Lipodystrophy Workshop
in Toronto
2nd International Workshop
on
Adverse Drug Reactions and Lipodystrophy in HIV
Toronto, Canada, September
2000
Osteopenia in HIV Infection
Andrew Carr, MD, Associate Professor of Medicine, HIV, Immunology and Infectious Diseases
Clinical Services Unit, St. Vincent's Hospital, Sydney, Australia
(01/15/2001)
Association of Severe Insulin Resistance With Both Loss
of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in
HIV Lipodystrophy
Dennis C. Mynarcik*;~ Margaret A. McNurlan;*
Roy T. Steigbigel;* Jack Fuhrer;* Marie C. Gelato
(01/10/2001)
full PDF
version also available.
Preliminary Study on Changes
in Lipids, Insulin and Body Changes During 12-Week STI: triglycerides
& cholesterol declined but CD4s decreased, viral load increased, some
developed clinical decline (1 person had PCP)
R Hoh(1),
J Troiano(2), M Christiansen, SG Deeks(1), MK Hellerstein(3) Univer of Cal-SF(1),
Gladstone Institute of Virology & Immunology-SF(2), Univer of Cal at
Berkely(3)
Switching PI Therapy
to Amprenavir & The Affect on Lipodystrophy & Lipids
Reduction in
lipid abnormalities during treatment with amprenavir in subjects experiencing
hyperlipidemia on a PI containing regimen
L. Pedneault, C. Garris,
S. Castillo, M. Rogers, N. Graham, L. Garrett, B. Akil, T. Scott, Glaxo
Wellcome, and Beverly Hills, Calif.
Incidence and risk factors
of statin or fibrate-induced hepatitis and myositis in HIV-infected patients
D. Lee, W.C. Mathews and E. Barber
LIVE REPORTS FROM TORONTO:
Written by Jules Levin